包装: | 10mg |
市场价: | 4043元 |
Cell lines | U266 and NCUMM-2 myeloma cell lines |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0-50 μM; 8 h |
Applications | In U266 and NCUMM-2 myeloma cell lines, ACHP (>10 μmol/L) inhibited the DNA binding activity of NF-κB after only 4 hours. ACHP also efficiently inhibited the phosphorylation of IκBαand p65 at 1 μmol/L after 20 minutes treatment. ACHP (10 μmol/L, 24h) also inhibited cell cycle progression and induced apoptosis. In NCUMM-2 cells, ACHP (10 μmol/L) efficiently induced apoptosis (15.8%) and a higher concentration of ACHP (50 μmol/L) induced apoptosis in 43.7% of the cells. |
产品描述 | IC50: 8.5 and 250 nM for IKKβ and IKKα, respectively ACHP is an IκB kinase inhibitor. Nuclear factor-KB (NF-KB) involved in cell survival and proliferation of multiple myeloma has been well established. In vitro: ACHP is selective for IKKα and IKKβ over IKK3, Syk and MAPKKK4 (IC50 >20 μM), DNA binding activity of NF-κB is inhibited. ACHP is an effective blockade NF-κB pathway in multiple myeloma cell lines, and induces cell growth arrest and apoptosis. It was observed that NF-KB is constitutively activated in all human myeloma cell lines, thus confirming the previous studies. In addition, It was found the phosphorylation of p65 subunit of NF-KB besides the phosphorylation of IKBA and the activation of NF-KB DNA binding and that various target genes of NF-KB including bcl-xL, XIAP, c-IAP1, cyclin D1, and IL-6 are up-regulated. 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinenitrile (ACHP) is a novel IKB kinase inhibitor. Treatment of myeloma cells with ACHP showed the cell growth was efficiently inhibited (IC50 values ranging from 18 to 35 Mmol/L) concomitantly with inhibition of the phosphorylation of IKBA/p65 and NF-KB DNA-binding, down-regulation of the NF-KB target genes, and then induction of apoptosis. In addition, the treatment of ACHP potentiated the cytotoxic effects of vincristine and melphalan (L-phenylalanine mustard), conventional antimyeloma drugs. These findings suggest that by blocking the antiapoptotic nature of myeloma cells endowed by the constitutive activation of NF-KB, IKB kinase inhibitors such as ACHP can sensitize myeloma cells to the cytotoxic effects of chemotherapeutic agents. In vivo: So far, no study in vivo has been conducted. Clinical trial: Clinical study has been conducted. Reference: |